Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Poorly inflamed carcinomas do not respond well to immune checkpoint blockade. Converting the tumour microenvironment into a functionally inflamed immune hub would extend the clinical benefit of immune therapy to a larger proportion of cancer patients. Here we show, by using comprehensive single-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Hicks, Kristin C., Chariou, Paul L., Ozawa, Yohei, Minnar, Christine M., Knudson, Karin M., Meyer, Thomas J., Bian, Jing, Cam, Margaret, Schlom, Jeffrey, Gameiro, Sofia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390765/
https://www.ncbi.nlm.nih.gov/pubmed/34446712
http://dx.doi.org/10.1038/s41467-021-25393-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390765/
https://www.ncbi.nlm.nih.gov/pubmed/34446712
http://dx.doi.org/10.1038/s41467-021-25393-x

Ejemplares similares